StockNews.com Upgrades Akebia Therapeutics (NASDAQ:AKBA) to “Hold”
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Wednesday. Separately, HC Wainwright reiterated a “buy” rating and issued a $7.50 price objective on shares of Akebia Therapeutics in a report on Thursday, January 23rd. View Our Latest […]
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Wednesday. Separately, HC Wainwright reiterated a “buy” rating and issued a $7.50 price objective on shares of Akebia Therapeutics in a report on Thursday, January 23rd. View Our Latest […]
